Effect of Neoadjuvant Chemotherapy on Peripheral Blood Treg Cells, Serum Levels of TGF-β1 and VEGF, and Expression of VEGF and CD105 in Cervical Cancer Tissues
GAO Xue-lian
Department of Obstetrics and Gynecology, Dianjiang People's Hospital of Chongqing; Chongqing Sichuan 400060 China
Abstract：【Objective】To study the influence of neoadjuvant chemotherapy on the ratio of Treg / CD4 cells in the peripheral blood, serum levels of TGF-β1 and VEGF, and the expression of VEGF and CD105 in tumor tissues.【Methods】A total of 97 patients with uterine cervical cancer (UCC) who were treated in our department from Mar 2014 to Mar 2017 were enrolled in this study (UCC group); all patients received neoadjuvant therapy. Meanwhile, 70 healthy women were included in the control group (HC group). The ratio of Treg/ CD4+ cells was measured by the flow cytometry assay, ; serum levels of TGF-β1 and VEGF were detected by ELISA assay, and the expression of VEGF and CD105 in the tumor tissue was evaluated by the immunohistochemistry.【Results】Before the neoadjuvant therapy, the ratio of the peripheral Treg/CD4 cells and the serum levels of TGF-β1 and VEGF were significantly higher in the UCC group than in the HC group (P＜0.05). The ratio of Treg/CD4 cells and the serum levels of TGF-β1 and VEGF were significantly decreased after the neoadjuvant therapy (P＜0.05). The expression of VEGF and CD105 in the tumor tissue of the UCC group significantly decreased after neoadjuvant therapy (P＜0.05). A positive correlation between VEGF and CD105 expression in the UCC tissue was found by the Pearson correlation analysis (r=0.557, P=0.032).【Conclusion】Neoadjuvant therapy can decrease the ratio of the peripheral Treg/CD4+ cells, reduce the release of TGF-β1, and downregulate the expression of CD105 and VEGF in the UCC tissue, thereby inhibiting angiogenesis and improving remission.
高雪莲. 新辅助化疗对宫颈癌患者外周血Treg细胞、血清TGF-β1、VEGF水平及组织VEGF、CD105表达的影响[J]. 医学临床研究, 2018, 35(4): 651-653.
GAO Xue-lian. Effect of Neoadjuvant Chemotherapy on Peripheral Blood Treg Cells, Serum Levels of TGF-β1 and VEGF, and Expression of VEGF and CD105 in Cervical Cancer Tissues. JOURNAL OF CLINICAL RESEARCH, 2018, 35(4): 651-653.
[1] 赫捷.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017; 26(1):1-7. [2] 温灏,吴小华.宫颈癌新辅助化疗的利与弊[J].中国妇产科临床杂志,2016,17(5):388-390. [3] Robova H,Rob L,Halaska MJ,et al.Review of neoadjuvant chemotherapy and trachelectomy:which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery [J] ?Curr Oncol Rep,2015,17(5):1-5. [4] Katsumata N,Yoshikawa H,Kobayashi H,et al.Phase Ⅲ randomised controlled trial of neoadjuvant chemotherapy plus radical surgeryvsradical surgery alone for stages ⅠB2,ⅡA2,and ⅡB cervical cancer:a Japan Clinical Oncology Group trial (JCOG 0102) [J].Br J Cancer,2013,108(10):1957-1963. [5] 吕琳.宫颈癌盆腔淋巴结转移的危险因素与预后分析[D].哈尔滨医科大学,2012. [6] 刘莉,陆远,王媛,等.EGFR、HER2、CXCR4在非小细胞肺癌中的表达及临床意义[J].现代生物医学进展,2014,14(6):1069-1073. [7] 沈佳惠,李胜泽.预测宫颈癌新辅助化疗敏感性的研究进展[J].中华全科医学,2014,12(12):1995-1997. [8] Oleinika K,Nibbs RJ,Graham GJ,et al.Suppression,subversion and escape:the role of regulatory T cells in cancer progression[J].Clin Exp Immunol,2013,171(1):36. [9] Nishikawa H.Regulatory T cells in cancer immunotherapy[J].Rinsho Ketsueki,2014,55(10):2183-2189. [10] 王静.紫杉醇联合顺铂化疗对宫颈癌患者外周血中调节性T细胞的影响[J].癌症进展,2013,11(3):240-242. [11] 马玉荣,胡彦萍,吴丽娟,等.新辅助化疗对子宫颈癌患者免疫功能的影响[J].临床合理用药杂志.2015,8 (2A):96-97. [12] Shevach EM.Garp as a therapeutic target for modulation of T regulatory cell function[J].Expert Opin Ther Targets,2017,21(2):191-200. [13] 于丹军,樊静,胡月,等.宫颈癌患者外周血中CD4+CD25+Foxp3+调节性T淋巴细胞及血清中IL-10、TGF-β的表达及其临床意义[J].标记免疫分析与临床,2016,23(10):1185-1190. [14] 冯春翠.新辅助化疗对宫颈癌患者血清及组织UPAR、TGF-β、CD105水平的影响[J].肿瘤药学,2017,7(17):1-4.
2018, Vol. 35 
